SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.18-5.1%Dec 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (8326)1/18/1999 10:08:00 AM
From: Tharos  Read Replies (1) of 17367
 
*** Blood trials done without consent

CHICAGO (AP) - A company conducted an ill-fated blood substitute
trial without the informed consent of patients in the study - some of
whom died, federal officials say. Baxter International Inc. was able
to test the substitute known as HemAssist without consent because of
a 1996 change in federal Food and Drug Administration regulations.
The changes broke a 50-year standard to get consent for nearly all
experiments on humans. They were designed to help research in
emergency medicine that could not happen if doctors took the time to
get consent. But the problems with the HemAssist trial are prompting
some medical ethicists to question the rule change. See
infobeat.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News